Endogenous cardiac natriuretic peptides protect the heart in a mouse model of dilated cardiomyopathy and sudden death.

Ventricular myocytes are known to show increased expression of the cardiac hormones atrial and brain natriuretic peptide (ANP and BNP, respectively) in response to pathological stress on the heart, but their function during the progression of nonischemic dilated cardiomyopathy remains unclear. In this study, we crossed a mouse model of dilated cardiomyopathy and sudden death, which we generated by cardioselectively overexpressing a dominant-negative form of the transcriptional repressor neuron-restrictive silencer factor (dnNRSF Tg mice), with mice lacking guanylyl cyclase-A (GC-A), a common receptor for ANP and BNP, to assess the effects of endogenously expressed natriuretic peptides during progression of the cardiomyopathy seen in dnNRSF Tg mice. We found that dnNRSF Tg;GC-A(-/-) mice were born normally, but then most died within 4 wk. The survival rates among dnNRSF Tg;GC-A(+/-) and dnNRSF Tg mice were comparable, but dnNRSF Tg;GC-A(+/-) mice showed greater systolic dysfunction and a more severe cardiomyopathic phenotype than dnNRSF Tg mice. Collectively, our findings suggest that endogenous ANP/BNP protects the heart against the death and progression of pathological remodeling in a mouse model of dilated cardiomyopathy and sudden death.

[1]  Y. Murakawa,et al.  Human atrial natriuretic peptide suppresses torsades de pointes in rabbits. , 2008, Circulation journal : official journal of the Japanese Circulation Society.

[2]  K. Nakao,et al.  Role of Natriuretic Peptide Receptor Guanylyl Cyclase-A in Myocardial Infarction Evaluated Using Genetically Engineered Mice , 2005, Hypertension.

[3]  E. Olson,et al.  Toward transcriptional therapies for the failing heart: chemical screens to modulate genes. , 2005, The Journal of clinical investigation.

[4]  K. Nakao,et al.  Overexpression of Brain Natriuretic Peptide Facilitates Neutrophil Infiltration and Cardiac Matrix Metalloproteinase-9 Expression After Acute Myocardial Infarction , 2004, Circulation.

[5]  G. Breithardt,et al.  Ventricular arrhythmias, increased cardiac calmodulin kinase II expression, and altered repolarization kinetics in ANP receptor deficient mice. , 2004, Journal of molecular and cellular cardiology.

[6]  J. Parratt,et al.  Sildenafil (Viagra) reduces arrhythmia severity during ischaemia 24 h after oral administration in dogs , 2004, British journal of pharmacology.

[7]  K. Nakao,et al.  NRSF regulates the fetal cardiac gene program and maintains normal cardiac structure and function , 2003, The EMBO journal.

[8]  Michael D. Schneider,et al.  Sizing up the heart: development redux in disease. , 2003, Genes & development.

[9]  W. Koch,et al.  Differential gene expression and genomic patient stratification following left ventricular assist device support. , 2003, Journal of the American College of Cardiology.

[10]  R. Quaife,et al.  Coordinate Changes in Myosin Heavy Chain Isoform Gene Expression Are Selectively Associated With Alterations in Dilated Cardiomyopathy Phenotype , 2002, Molecular medicine.

[11]  Daniel Levy,et al.  Long-term trends in the incidence of and survival with heart failure. , 2002, The New England journal of medicine.

[12]  K. Nakao,et al.  Guanylyl Cyclase-A Inhibits Angiotensin II Type 1A Receptor-Mediated Cardiac Remodeling, an Endogenous Protective Mechanism in the Heart , 2002, Circulation.

[13]  A. Maisel,et al.  B-type natriuretic peptide levels: diagnostic and prognostic in congestive heart failure: what's next? , 2002, Circulation.

[14]  R. Quaife,et al.  Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. , 2002, The New England journal of medicine.

[15]  H. Ogawa,et al.  Pathophysiological significance and clinical application of ANP and BNP in patients with heart failure. , 2001, Canadian journal of physiology and pharmacology.

[16]  E. Hartter,et al.  Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. , 2001, Journal of the American College of Cardiology.

[17]  J. Knowles,et al.  Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice. , 2001, The Journal of clinical investigation.

[18]  Kenji Nakamura,et al.  Cardiac fibrosis in mice lacking brain natriuretic peptide. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[19]  C. Frampton,et al.  Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations , 2000, The Lancet.

[20]  F. Zannad,et al.  Incidence, clinical and etiologic features, and outcomes of advanced chronic heart failure: the EPICAL Study. Epidémiologie de l'Insuffisance Cardiaque Avancée en Lorraine. , 1999, Journal of the American College of Cardiology.

[21]  M. F. Goy,et al.  Natriuretic peptide receptor 1 expression influences blood pressures of mice in a dose-dependent manner. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[22]  H. S. Kim,et al.  Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[23]  M. Wilkins,et al.  The natriuretic-peptide family , 1997, The Lancet.

[24]  D. Garbers,et al.  Salt-resistant hypertension in mice lacking the guanylyl cyclase-A receptor for atrial natriuretic peptide , 1995, Nature.

[25]  Meihong Lin,et al.  Natriuretic peptides inhibit angiotensin II-induced proliferation of rat cardiac fibroblasts by blocking endothelin-1 gene expression. , 1995, The Journal of clinical investigation.

[26]  K. Kugiyama,et al.  Localization and Mechanism of Secretion of B‐Type Natriuretic Peptide in Comparison With Those of A‐Type Natriuretic Peptide in Normal Subjects and Patients With Heart Failure , 1994, Circulation.

[27]  C. Ibukiyama,et al.  The beneficial effects of atrial natriuretic peptide on arrhythmias and myocardial high-energy phosphates after reperfusion. , 1994, Cardiovascular research.

[28]  Michihisa Jougasaki,et al.  Different Secretion Patterns of Atrial Natriuretic Peptide and Brain Natriuretic Peptide in Patients With Congestive Heart Failure , 1993, Circulation.

[29]  D. Goeddel,et al.  Molecular Biology of the Natriuretic Peptides and Their Receptors , 1992, Circulation.

[30]  K. Nakao,et al.  Molecular biology and biochemistry of the natriuretic peptide system. II: Natriuretic peptide receptors. , 1992, Journal of hypertension.

[31]  S. Chien,et al.  Regulation of cardiac gene expression during myocardial growth and hypertrophy: molecular studies of an adaptive physiologic response , 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[32]  H. Imura,et al.  Natriuretic peptides as cardiac hormones in normotensive and spontaneously hypertensive rats. The ventricle is a major site of synthesis and secretion of brain natriuretic peptide. , 1991, Circulation research.

[33]  K. Inouye,et al.  Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. , 1991, The Journal of clinical investigation.

[34]  Orton,et al.  INTRAVENOUS NESIRITIDE, A NATRIURETIC PEPTIDE, IN THE TREATMENT OF DECOMPENSATED CONGESTIVE HEART FAILURE , 2000 .

[35]  藤崎 裕幸.  Natriuretic peptides inhibit angiotensin II-induced proliferation of rat cardiac fibroblasts by blocking endothelin-1 gene expression , 1996 .